liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Clinical Pharmacology.
Show others and affiliations
2000 (English)In: Clinical neuropharmacology, ISSN 0362-5664, Vol. 23, no 6, 304-317 p.Article in journal (Refereed) Published
Abstract [en]

Chronic hepatic encephalopathy (HE) is a neuropsychiatric syndrome that arises in liver-impaired subjects. Patients with HE display various neuropsychiatric symptoms including affective disturbances and may therefore likely receive treatment with novel thymoleptics like citalopram (CIT). The simultaneous pharmacokinetic and pharmacodynamic outcome of the commonly used serotonin-selective thymoleptic drugs in liver-impaired subjects with pending chronic HE is far from understood today. We therefore investigated the effects of chronic, body-weight-adjusted (10 mg ╖ kg-1 ╖ day-1), treatment with CIT in rats with and without portacaval shunts (PCS). Open-field activity was monitored. The 5-HT, 5-HIAA, noradrenaline (NA), and dopamine (DA) output were assessed in the frontal neocortex. The racemic levels of CIT and its metabolites DCIT and DDCIT, including the S- and R-enantiomers, were determined in serum, brain parenchyma, and extracellular fluid. The rats with PCS showed higher (2-3-fold) levels of CIT than rats undergoing a sham treatment with CIT in all compartments investigated. The PCS rats also showed elevated levels of DCIT and DDCIT. No major differences in the S/R ratios between PCS rats and control rats could be detected. The CIT treatment resulted in neocortical output differences between PCS rats and control rats mainly within the 5-HT and DA systems but not within the NA system. For the 5-HT system, this change was further evidenced by outspoken elevation in 5-HT output after KCl-depolarizing challenges. Moreover, the CIT treatment to PCS rats was shown to "normalize" the metabolic turnover of 5-HT, measured as a profound lowering of a basal elevation in the 5-HIAA levels. The CIT treatment resulted in an increased or "normalized" behavioral activity in the PCS group. Therefore, a dose-equal chronic treatment with CIT in PCS rats produced pharmacokinetic and pharmacodynamic changes not observed in control rats. The results further support the contention of an altered 5-HT neurotransmission prevailing in the chronic HE condition. However, the tentatively beneficial behavioral response also seen following chronic CIT treatment to PCS rats in this study has to be viewed in relation to both the pharmacokinetic and pharmacodynamic changes observed.

Place, publisher, year, edition, pages
2000. Vol. 23, no 6, 304-317 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-26741DOI: 10.1097/00002826-200011000-00003Local ID: 11336OAI: diva2:247291
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2011-01-14

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Carlsson, BjörnAhlner, JohanBengtsson, Finn
By organisation
Faculty of Health SciencesClinical PharmacologyDepartment of Clinical PharmacologyPsychiatryDepartment of Psychiatry
In the same journal
Clinical neuropharmacology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 63 hits
ReferencesLink to record
Permanent link

Direct link